IceCure Medical Ltd (NASDAQ:ICCM) Sees Significant Decline in Short Interest

IceCure Medical Ltd (NASDAQ:ICCM) was the recipient of a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 393,100 shares, a decrease of 9.2% from the August 31st total of 432,900 shares. Currently, 1.7% of the shares of the company are short sold. Based on an average daily volume of 542,000 shares, the days-to-cover ratio is presently 0.7 days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a research report on Thursday, September 12th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC purchased a new stake in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical as of its most recent SEC filing. 0.62% of the stock is currently owned by institutional investors.

IceCure Medical Stock Performance

NASDAQ:ICCM opened at $0.61 on Tuesday. IceCure Medical has a 52-week low of $0.55 and a 52-week high of $1.57. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.54 and a current ratio of 2.97. The firm has a market capitalization of $27.83 million, a PE ratio of -1.85 and a beta of 0.56. The stock has a 50-day simple moving average of $0.66 and a two-hundred day simple moving average of $0.90.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. IceCure Medical had a negative net margin of 410.22% and a negative return on equity of 111.27%. During the same period in the prior year, the firm posted ($0.09) EPS. Analysts forecast that IceCure Medical will post -0.27 EPS for the current year.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.